ACM
FBRX icon

Altium Capital Management’s Forte Biosciences FBRX Stock Holding History

Altium Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,382
Closed -$4.61M – 140
2021
Q1 		$4.61M Buy
+5,382
New +$4.41M 1.28% 27

Other funds holding FBRX

FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Altium Capital Management's FBRX Position: Q2 2021 in Review

Altium Capital Management sold out of Forte Biosciences (FBRX) in Q2 2021, closing a stake of 5,382 shares — an estimated $4.61M sold.

Altium Capital Management first reported a position in FBRX in Q1 2021 and held it in 1 quarter. The position peaked at $4.61M in Q1 2021. 75 funds tracked by Wall St. Rank hold FBRX as of Q2 2021.

  • Altium Capital Management reported no remaining Forte Biosciences position as of Q2 2021 after selling out during the quarter.
  • Altium Capital Management sold 5,382 Forte Biosciences shares in Q2 2021, an estimated $4.61M.
  • Altium Capital Management first reported a position in Forte Biosciences in Q1 2021 and held it in 1 quarter.
  • Altium Capital Management's Forte Biosciences position peaked at $4.61M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2021.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.